🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
1.000
+0.090 (9.89%)
Nov 19, 2026, 4:00 PM EST - Market closed

Aardvark Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
18.9813.795.312.172.7
Research & Development
56.9948.9417.364.487.17
Operating Expenses
75.9762.7322.797.4210.36
Operating Income
-75.97-62.73-22.79-7.42-10.36
Interest & Investment Income
3.255.142.411.420.12
EBT Excluding Unusual Items
-72.72-57.59-20.37-5.99-10.24
Gain (Loss) on Sale of Investments
-0.04-0.01-0.22-1.22-2.32
Asset Writedown
-----1
Pretax Income
-72.76-57.59-20.59-7.21-13.56
Net Income
-72.76-57.59-20.59-7.21-13.56
Net Income to Common
-72.76-57.59-20.59-7.21-13.56
Net Income Growth
-----
Shares Outstanding (Basic)
2220444
Shares Outstanding (Diluted)
2220444
Shares Change
43.78%391.06%0.90%1.78%-
EPS (Basic)
-3.33-2.93-5.15-1.82-3.49
EPS (Diluted)
-3.33-2.93-5.15-1.82-3.49
EPS Growth
-----

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Free Cash Flow
-66.81-54.27-18.2-5.82-10.54
Free Cash Flow Per Share
-3.06-2.77-4.55-1.47-2.71
EBITDA
-75.93-62.69-22.77--
D&A For EBITDA
0.040.040.02--
EBIT
-75.97-62.73-22.79-7.42-10.36
SEC Filings: 10-K · 10-Q